1.	Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00141, CTRG-HC06/21/05, N01CM62205, CDR0000463519, NCI-7237, 7237, NCT00321594
2.	A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PXD101-CLN-8, PXD101-040-EU, NCT00421889
3.	Trial of PXD101 in Combination With Idarubicin to Treat Acute Myeloid Leukemia (AML) Not Suitable for Standard Intensive Therapy Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PXD101-CLN-15, NCT00878722
4.	Study of PXD101 and Doxorubicin to Treat Soft Tissue Sarcomas Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PXD101-CLN-14, NCT00878800
5.	Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PXD101-301-G, NCT00131261
6.	Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00144, PHL-041, PMH-PHL-041, CDR0000459798, NCI-7267, N01CM62203, 7267, NCT00301756
7.	PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-01096, S0520, CDR0000462614, U10CA032102, SWOG-S0520, NCT00303953
8.	Clinical Trial of PXD101 in Patients With T-Cell Lymphomas Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PXD101-CLN-6, NCT00274651
9.	PXD101 in Treating Patients With Acute Myeloid Leukemia Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02838, PHII-68, N01CM62209, CDR0000487508, CCC-PHII-68, 7265, NCI-7265, CHNMC-PHII-68, NCT00357032
10.	PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02839, PHII 67, N01CM62209, CDR0000489194, CCC-PHII-67, 7255, NCI-7255, NCT00365053
11.	Belinostat in Treating Patients With Myelodysplastic Syndromes Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00143, MC0581, CDR0000489197, N01CM17104, MAYO-MC0581, 7258, NCI-7258, NCT00357162
12.	Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: 080033, 08-C-0033, NCI-08-C-0033, 8174, NCI-P07249, NCT00589290
13.	Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PXD101-CLN-19, 2008-005843-40, NCT00865969
14.	Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2010-01663, GOG-0126T, U10CA027469, CDR0000656707, NCT00993616
15.	Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PXD101-CLN-17, NCT00873119
16.	PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas Phase: Phase I Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: NCI-2009-01052, COMIRB 05-0705, UCHSC-COMIRB-05-0705, UCHSC-05-0705, NCI-7281, CDR0000476293, U01CA099176, 7281, NCT00348985
17.	Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00142, PHI-53, CDR0000479715, U01CA062505, U01CA099168, CCC-PHI-53, 7251, NCI-7251, NCT00334789
18.	Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00146, 14510A, U01CA069852, U01CA062491, U01CA132123, UCCRC-14510A, 7285, NCI-7285, NCT00351975
19.	Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PXD101-CLN-4, NCT00413322
20.	Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PXD101-CLN-9, NCT00413075
21.	A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PXD101-CLN-20, NCT01317927